SCHEMBL9701428

SCHEMBL9701428

CCC(=O)CC(=O)c1ccc(OC)cc1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.60
LMNA P02545 1/20 0.60
ALOX15 P16050 1/20 0.60
APEX1 P27695 1/20 0.60
MAPK1 P28482 1/20 0.60
RECQL P46063 1/20 0.60
HSD17B10 Q99714 1/20 0.60
TDP1 Q9NUW8 1/20 0.60
HDAC3 O15379 4/20 0.59
HDAC4 P56524 4/20 0.59
HDAC1 Q13547 4/20 0.59
HDAC7 Q8WUI4 4/20 0.59
HDAC2 Q92769 4/20 0.59
HDAC10 Q969S8 4/20 0.59
HDAC11 Q96DB2 4/20 0.59
HDAC8 Q9BY41 4/20 0.59
HDAC6 Q9UBN7 4/20 0.59
HDAC9 Q9UKV0 4/20 0.59
HDAC5 Q9UQL6 4/20 0.59
GSK3B P49841 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11139976 0.95 ALDH1A1 (0.55) ALDH1A1LMNAALOX15APEX1MAPK1
SCHEMBL29219054 0.90 ALDH1A1 (0.66) ALDH1A1LMNAALOX15APEX1MAPK1
SCHEMBL153386 0.86 ALDH1A1 (0.76) ALDH1A1LMNAALOX15APEX1MAPK1
SCHEMBL9483307 0.86 MAPT (0.48) ALDH1A1LMNAALOX15MAPK1TDP1
SCHEMBL28029377 0.85 HDAC8 (0.65) ALDH1A1LMNAALOX15APEX1MAPK1
SCHEMBL459470 0.84 KMT2A (0.70) ALDH1A1LMNAALOX15APEX1MAPK1
SCHEMBL6284359 0.84 MMP1 (0.63) ALDH1A1HSD17B10HDAC3HDAC4HDAC1
SCHEMBL585367 0.83 HDAC1 (0.57) ALDH1A1LMNAALOX15APEX1MAPK1
1,4-Dimethoxybenzene SCHEMBL27728279 0.82 NR1I2 (0.58) TDP1HDAC3HDAC4HDAC1HDAC7
SCHEMBL11327776 0.82 HDAC1 (0.57) ALDH1A1LMNAALOX15APEX1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108689973-A A kind of preparation method of 2- ethyls -3- (4- hydroxy benzoyls) benzofuran 华中科技大学 2018-10-23 CN claimed
US-RE50083-E1 URAT1 inhibitor and use thereof JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) 2024-08-20 US disclosed
CN-117586272-A Heterocyclic compound, preparation method and application thereof in medicine 苏州信诺维医药科技股份有限公司 2024-02-23 CN disclosed
CN-111615515-B Heterocyclic compound, preparation method and application thereof in medicine 苏州信诺维医药科技股份有限公司 2023-11-24 CN disclosed
EP-3741759-B1 IMIDAZO[1,2-A]PYRIMIDINE AND IMIDAZO[1,2-C]PYRIMIDINE COMPOUNDS AND USE THEREOF IN THE TREATMENT OF HYPERURICEMIA AND GOUT EVOPOINT BIOSCIENCES CO LTD (CN) 2023-08-23 EP disclosed
EP-3741759-B1 IMIDAZO[1,2-A]PYRIMIDINE AND IMIDAZO[1,2-C]PYRIMIDINE COMPOUNDS AND USE THEREOF IN THE TREATMENT OF HYPERURICEMIA AND GOUT EVOPOINT BIOSCIENCES CO LTD (CN) 2023-08-23 EP disclosed
US-11597725-B2 URAT1 inhibitor for promoting uric acid excretion JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) 2023-03-07 US disclosed
US-11453674-B2 Heterocyclic compound, preparation method and use thereof in medicine Evopoint Biosciences Co., Ltd. (CN) 2022-09-27 US disclosed
EP-3543240-B1 URAT1 INHIBITOR AND USE THEREOF JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO LTD (CN) 2022-07-06 EP disclosed
EP-3543240-B1 URAT1 INHIBITOR AND USE THEREOF JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO LTD (CN) 2022-07-06 EP disclosed
US-20180282321-A1 COMPOUND FOR TREATING OR PREVENTING HYPERURICEMIA OR GOUT JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) 2018-10-04 US disclosed
EP-3348557-A1 COMPOUND FOR TREATING OR PREVENTING HYPERURICEMIA OR GOUT Jiangsu Atom Bioscience And Pharmaceutical Co., Ltd (CN) 2018-07-18 EP disclosed
EP-3348557-A1 COMPOUND FOR TREATING OR PREVENTING HYPERURICEMIA OR GOUT Jiangsu Atom Bioscience And Pharmaceutical Co., Ltd (CN) 2018-07-18 EP disclosed
WO-2018090921-A1 URAT1 INHIBITOR AND USE THEREOF 江苏新元素医药科技有限公司 2018-05-24 WO disclosed
WO-2017041732-A1 COMPOUND FOR TREATING OR PREVENTING HYPERURICEMIA OR GOUT 江苏新元素医药科技有限公司 2017-03-16 WO disclosed
US-5112820-A Vision defects STERLING DRUG INC. (US) 1992-05-12 US disclosed
US-5109135-A 2- or 3-aminomethyl-4-amino-3,4-dihydro-2H-1,4-benzoxazine intermediates STERLING DRUG INC. (US) 1992-04-28 US disclosed
US-5066803-A Chemical intermediates for analgesics STERLING DRUG INC. (US) 1991-11-19 US disclosed
WO-1990007505-A1 2- AND 3-AMINOMETHYL-6-ARYLCARBONYL-2,3-DIHYDROPYRROLO[1,2,3-de]-1,4-BENZOXAZINES STERLING DRUG INC. (US) 1990-07-12 WO disclosed
US-4939138-A 2- and 3-aminomethyl-6-arylcarbonyl-2,3-dihydropyrrolo(1,2,3-DE)-1,4-benzoxazines STERLING DRUG INC. (US) 1990-07-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11597725-B2 URAT1 inhibitor for promoting uric acid excretion SLC10A6, SLC10A1, SLC28A1 ALDH1A1 326/4885LMNA 3692/4885ALOX15 2596/4885
US-20180282321-A1 COMPOUND FOR TREATING OR PREVENTING HYPERURICEMIA OR GOUT SLC10A1, SLC5A1, SLC10A6 ALDH1A1 716/4885LMNA 2942/4885ALOX15 1010/4885
US-11453674-B2 Heterocyclic compound, preparation method and use thereof in medicine PAH, NLRP3, CYP11B2 ALDH1A1 1562/4885LMNA 830/4885ALOX15 411/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.